Compare Lululemon Athletica Inc (LULU) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Sana Biotechnology Inc — how do they compare? Lululemon Athletica Inc trades at $119.52 (market cap $14.26B), while Sana Biotechnology Inc trades at $3.68 (market cap $1.13B). The key difference: Lululemon Athletica Inc is far larger — about 12.6× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals.
| LULU | SANA | |
|---|---|---|
Market Cap | $14.26B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $215.88 | $5.92 |
52-Week Low | $105.43 | $2.68 |
Enterprise Value | $14.89B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon stock trades at $120.88, down 5.41% amid broader market weakness in the premium apparel sector. The company maintains strong fundamentals with a P/E of 10.17, net income margin of 13.03%, and consistent earnings beats. Technical indicators show a bullish moving average trend despite overbought RSI readings, with key resistance near $129.
Investment outlook remains positive given undervaluation metrics and international growth potential, though risks include U.S. demand softness and competitive pressures. Analyst consensus targets $129.29 with 41% buy ratings, suggesting moderate upside from current levels.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
